尽管季度亏损，Dianthus Therapeutics的股价上涨，主要得益于积极的第三阶段决策和一轮重大融资。 Dianthus Therapeutics' stock rose despite a quarterly loss, fueled by a positive Phase 3 decision and a major funding round.

迪安修斯治疗 (DNTH) 报告季度每股1.43美元的亏损,缺失估计,并发布负面的财务指标,但其股票在其主要药物DNTH103的早期第三阶段决定和成功的7.19亿美元大规模公开募股后上. Dianthus Therapeutics (DNTH) reported a quarterly loss of $1.43 per share, missing estimates, and posted negative financial metrics, yet its stock rose following an early Phase 3 go decision for its lead drug DNTH103 and a successful $719 million upsized public offering. 尽管有财务结果,但包括Raymond James和Wedbush在内的公司对分析员的升级提高了投资者的信心,促使交易量增加。 Despite the financial results, analyst upgrades from firms including Raymond James and Wedbush boosted investor confidence, driving increased trading volume. 该公司总部设在纽约,成立于2019年,重点是针对自发免疫和炎症的补充治疗。 The company, based in New York and founded in 2019, focuses on complement therapeutics for autoimmune and inflammatory diseases. 首席执行官Marino Garcia于2026年3月12日出售了1 002万美元股票,3月14日以77.86美元结束库存,12个月范围为13.36美元至88.02美元,并获得协商一致的“Moderate Buy”评级。 CEO Marino Garcia sold $10.02 million in shares on March 12, 2026, while the stock closed at $77.86 on March 14, with a 12-month range of $13.36 to $88.02 and a consensus “Moderate Buy” rating.